Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.79% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Financials | 0.79% |
| 4 | Healthcare | 0.66% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11851
CALL
BRC Inc
BRCC
$122M
| $90.4K | ﹤0.01% |
6,900
+680
| +11% | +$12.6K |
|
11852
PUT
Opko Health
OPK
$1.13B
| $90K | ﹤0.01% |
68,200
+30,700
| +82% | +$42K |
|
|
IGMS
11853
DELISTED
IGM Biosciences
IGMS
| $89.9K | ﹤0.01% |
80,311
+55,131
| +219% | +$67.3K |
|
11854
CALL
Upland Software
UPLD
$13.3M
| $89.9K | ﹤0.01% |
+4,610
| New | +$103K |
|
|
NXXT
11855
NextNRG Inc
NXXT
$40M
| $89.5K | ﹤0.01% |
+32,303
| New | +$98.6K |
|
|
BCYC
11856
PUT
Bicycle Therapeutics
BCYC
$305M
| $89K | ﹤0.01% |
+12,800
| New | +$102K |
|
|
MURA
11857
CALL
DELISTED
Mural Oncology
MURA
| $88.4K | ﹤0.01% |
35,800
+9,200
| +35% | +$21.7K |
|
11858
CALL
Kodiak Sciences
KOD
$2.47B
| $88.4K | ﹤0.01% |
+23,700
| New | +$83.9K |
|
|
FFWM
11859
PUT
DELISTED
First Foundation Inc
FFWM
| $88.2K | ﹤0.01% |
+17,300
| New | +$88.6K |
|
|
DSM
11860
BNY Mellon Strategic Municipal Bond Fund
DSM
$288M
| $87.9K | ﹤0.01% |
15,700
-6,007
| -28% | -$33.7K |
|
11861
CALL
Kyverna Therapeutics
KYTX
$532M
| $87.8K | ﹤0.01% |
+28,600
| New | +$70.7K |
|
11862
ReNew
RNW
$2.49B
| $87.2K | ﹤0.01% |
+12,618
| New | +$82.4K |
|
|
BGFV
11863
DELISTED
Big 5 Sporting Goods
BGFV
| $87K | ﹤0.01% |
+61,246
| New | +$65.7K |
|
|
THRD
11864
CALL
DELISTED
Third Harmonic Bio
THRD
| $86.9K | ﹤0.01% |
16,000
-4,300
| -21% | -$21.4K |
|
11865
Werewolf Therapeutics
HOWL
$48.1M
| $86.8K | ﹤0.01% |
79,602
+30,261
| +61% | +$31.1K |
|
|
BZAI
11866
CALL
Blaize Holdings
BZAI
$71.9M
| $86.7K | ﹤0.01% |
29,100
-7,300
| -20% | -$18K |
|
11867
PUT
Allogene Therapeutics
ALLO
$705M
| $86.3K | ﹤0.01% |
76,400
+24,700
| +48% | +$32.8K |
|
|
AIFC
11868
PUT
AI Financial Corp
AIFC
$83.2M
| $86.3K | ﹤0.01% |
11,900
-17,800
| -60% | -$125K |
|
|
YQ
11869
17 Education & Technology Group
YQ
$20.8M
| $86.2K | ﹤0.01% |
39,339
-7,577
| -16% | -$14.7K |
|
11870
PUT
Bioventus
BVS
$954M
| $86.1K | ﹤0.01% |
13,000
-20,600
| -61% | -$146K |
|
11871
PUT
Amylyx Pharmaceuticals
AMLX
$4.13B
| $85.9K | ﹤0.01% |
13,400
-22,800
| -63% | -$111K |
|
11872
Creative Realities
CREX
$38.6M
| $85.9K | ﹤0.01% |
25,477
+6,205
| +32% | +$14.9K |
|
11873
Castor Maritime
CTRM
$23.9M
| $85.3K | ﹤0.01% |
40,435
+13,572
| +51% | +$30.3K |
|
11874
PUT
FIGS
FIGS
$2.53B
| $85.2K | ﹤0.01% |
15,100
-53,500
| -78% | -$247K |
|
11875
RAVE Restaurant Group
RAVE
$44.2M
| $85.1K | ﹤0.01% |
30,939
+16,473
| +114% | +$41.6K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass deployed $32.3B of net new capital in Q2 2025, opening 1,720 new positions and adding to 5,716 existing holdings. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
By sector, the portfolio is most concentrated in Technology at 1.8% of assets, up from 1.6% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B trimmed.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.